• Risk
  • There is also an ongoing evaluation for the risk of bone fractures with other SGLT2 inhibitors to evaluate the need for drug label changes or additional studies. (empr.com)
  • In May 2015, the FDA issued a drug safety communication cautioning about the risk for ketoacidosis with SGLT2 inhibitors and saying the agency would continue to study this issue. (newsinferno.com)
  • There is low risk of clinically relevant pharmacokinetics drug interactions because of the metabolic pathway of SGLT2. (wikipedia.org)